Literature DB >> 22370711

Late effect of atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes.

Hideki Tsushima1, Masako Iwanaga, Yasushi Miyazaki.   

Abstract

Leukemia was the first malignancy linked to radiation exposure in atomic bomb survivors. Clear evidence of the dose-dependent excess risk of three major types of leukemia (acute lymphocytic leukemia, acute myeloid leukemia [AML], and chronic myeloid leukemia) was found, especially in people exposed at young ages. Such leukemia risks were at their highest in the late 1950s, and declined gradually thereafter over the past 50 years. Findings from recent risk analyses, however, suggest the persistence of AML risk even after 1990, and evidence of increased risk of myelodysplastic syndromes (MDS) due to atomic bomb radiation has recently been shown. High-risk MDS and forms involving complex chromosomal aberrations were found to be much more frequent in people exposed to higher radiation doses. These lines of epidemiological evidence suggest that the risk of radiation-induced hematological malignancies has persisted for six decades since the initial exposure.

Entities:  

Mesh:

Year:  2012        PMID: 22370711     DOI: 10.1007/s12185-012-1002-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  10 in total

1.  Incidence of leukemia in survivors of the atomic bomb in Hiroshima and Nagasaki, Japan.

Authors:  J H FOLLEY; W BORGES; T YAMAWAKI
Journal:  Am J Med       Date:  1952-09       Impact factor: 4.965

2.  Leukemia in atomic bomb survivors, Hiroshima and Nagasaki, 1 October 1950--30 September 1966.

Authors:  T Ishimaru; T Hoshino; M Ichimaru; H Okada; T Tomiyasu
Journal:  Radiat Res       Date:  1971-01       Impact factor: 2.841

3.  Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors.

Authors:  Masako Iwanaga; Wan-Ling Hsu; Midori Soda; Yumi Takasaki; Masayuki Tawara; Tatsuro Joh; Tatsuhiko Amenomori; Masaomi Yamamura; Yoshiharu Yoshida; Takashi Koba; Yasushi Miyazaki; Tatsuki Matsuo; Dale L Preston; Akihiko Suyama; Kazunori Kodama; Masao Tomonaga
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

4.  Proposals for the classification of the myelodysplastic syndromes.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1982-06       Impact factor: 6.998

5.  Ionizing radiation and leukemia mortality among Japanese Atomic Bomb Survivors, 1950-2000.

Authors:  David Richardson; Hiromi Sugiyama; Nobuo Nishi; Ritsu Sakata; Yukiko Shimizu; Eric J Grant; Midori Soda; Wan-Ling Hsu; Akihiko Suyama; Kazunori Kodama; Fumiyoshi Kasagi
Journal:  Radiat Res       Date:  2009-09       Impact factor: 2.841

6.  Incidence of leukemia in atomic bomb survivors belonging to a fixed cohort in Hiroshima and Nagasaki, 1950--71. Radiation dose, years after exposure, age at exposure, and type of leukemia.

Authors:  M Ichimaru; T Ishimaru; J L Belsky
Journal:  J Radiat Res       Date:  1978-09       Impact factor: 2.724

7.  Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987.

Authors:  D L Preston; S Kusumi; M Tomonaga; S Izumi; E Ron; A Kuramoto; N Kamada; H Dohy; T Matsuo; T ] Matsui T [corrected to Matsuo
Journal:  Radiat Res       Date:  1994-02       Impact factor: 2.841

8.  Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1976-08       Impact factor: 6.998

9.  Reclassification of leukemia among A-bomb survivors in Nagasaki using French-American-British (FAB) classification for acute leukemia.

Authors:  T Matsuo; M Tomonaga; J M Bennett; K Kuriyama; F Imanaka; A Kuramoto; N Kamada; M Ichimaru; S C Finch; A V Pisciotta
Journal:  Jpn J Clin Oncol       Date:  1988-06       Impact factor: 3.019

10.  Cytogenetic and molecular changes in leukemia among atomic bomb survivors.

Authors:  N Kamada; K Tanaka; N Oguma; K Mabuchi
Journal:  J Radiat Res       Date:  1991-12       Impact factor: 2.724

  10 in total
  6 in total

1.  Examining temporal effects on cancer risk in the international nuclear workers' study.

Authors:  Robert D Daniels; Stephen J Bertke; David B Richardson; Elisabeth Cardis; Michael Gillies; Jacqueline A O'Hagan; Richard Haylock; Dominique Laurier; Klervi Leuraud; Monika Moissonnier; Isabelle Thierry-Chef; Ausrele Kesminiene; Mary K Schubauer-Berigan
Journal:  Int J Cancer       Date:  2017-03-15       Impact factor: 7.396

2.  Medical conditions and risk of adult myeloid leukemia.

Authors:  Kimberly J Johnson; Cindy M Blair; James M Fink; James R Cerhan; Michelle A Roesler; Betsy A Hirsch; Phuong L Nguyen; Julie A Ross
Journal:  Cancer Causes Control       Date:  2012-05-11       Impact factor: 2.506

Review 3.  Potential relationship between inadequate response to DNA damage and development of myelodysplastic syndrome.

Authors:  Ting Zhou; Peishuai Chen; Jian Gu; Alexander J R Bishop; Linda M Scott; Paul Hasty; Vivienne I Rebel
Journal:  Int J Mol Sci       Date:  2015-01-05       Impact factor: 5.923

4.  Protective Effect of Onion Extract on Bleomycin-Induced Cytotoxicity and Genotoxicity in Human Lymphocytes.

Authors:  Yoon Hee Cho; Joong Won Lee; Hae Dong Woo; Sunyeong Lee; Yang Jee Kim; Younghyun Lee; Sangah Shin; Hyojee Joung; Hai Won Chung
Journal:  Int J Environ Res Public Health       Date:  2016-02-19       Impact factor: 3.390

5.  Chronic myeloid leukaemia following repeated exposure to chest radiography and computed tomography in a patient with pneumothorax: A case report and literature review.

Authors:  Fang-He Ju; Xu-Bo Gong; Li-Bin Jiang; Hui-Hua Hong; Jun-Chao Yang; Ting-Zhen Xu; Y U Chen; Zhen Wang
Journal:  Oncol Lett       Date:  2016-02-17       Impact factor: 2.967

6.  Therapy-related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor.

Authors:  Selin Kucukyurt; Yeliz Yagiz Ozogul; Abdulkadir Ercaliskan; Levent Kabasakal; Ahmet Emre Eskazan
Journal:  Cancer Rep (Hoboken)       Date:  2020-09-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.